Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Cosentyx® - IL-17A inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03769168 (CAIN457F2304E1 - extension study)
Psoriatic arthritis
Phase 3
64
Number of participants with JIA ACR30 response
Secukinumab 75 mg/0.5 ml
Secukinumab 150 mg/1.0 ml
Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and
enthesitis related arthritis
Target Patients
Read-out Milestone(s)
2025
Publication
TBD
NCT04156620 INVIGORATE-1 (CAIN457P12301)
Axial spondyloarthritis
Phase 3
500
The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis
International Society criteria) response
Secukinumab intravenous (i.v.) regimen
Placebo intravenous (i.v.) regimen
Patients with active axial spondyloarthritis
Primary (week 16): 2022; Final: 2023
2023
59 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation